losartan has been researched along with Epidermolysis Bullosa Junctionalis, Disentis Type in 1 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tartaglia, G | 1 |
| Park, PH | 1 |
| Alexander, MH | 1 |
| Nyström, A | 1 |
| Rosenbloom, J | 1 |
| South, AP | 1 |
1 other study available for losartan and Epidermolysis Bullosa Junctionalis, Disentis Type
| Article | Year |
|---|---|
Trametinib-Induced Epidermal Thinning Accelerates a Mouse Model of Junctional Epidermolysis Bullosa.
Topics: Animals; Epidermis; Epidermolysis Bullosa, Junctional; Losartan; Mice; Skin | 2023 |